checkAd

     145  0 Kommentare KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

    KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17. KalVista is a Silver-level sponsor of the meeting. The presentations are:

    • Relationship Between Time to ​On-demand Treatment and Quality of Life During Hereditary Angioedema Attacks: Sandra Christiansen, Timothy Craig, Maeve O’Connor, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Tomas Andriotti, Paul Audhya, Paula Busse.​ Results shared as an oral presentation as part of Abstract Oral Presentations: Session 1 on Saturday, March 16 at 9:15 am EST in the Magnolia Room
    • Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Paul Audhya, Sandra Christiansen. Results shared as an oral poster presentation and Q&A
    • Delayed On-Demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, Maeve O’Connor, Julie Ulloa, Sherry Danese, Vibha Desai, Paul Audhya, Paula Busse. Results shared as an oral poster presentation and Q&A
    • Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Vibha Desai, Julie Ulloa, Sherry Danese, Paul Audhya, Timothy Craig, Maeve O’Connor (presenter-only). Results shared as an oral poster presentation and Q&A
    • Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Michael Manning, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry
    • Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Daniel F. Soteres, Anete S. Grumach, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn Burnette
    • Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Hilary Longhurst, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Ricardo Zwiener

    All poster presentations will take place on Friday, March 15 starting at 7:20 p.m. EST in the Vetiver Room.

    Seite 1 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at …